COVID-19 Vaccine Reactogenicity Among Young Children

Sabrina A Madni; Kieauna Strickland; Victoria Konrad; Lauren Head Zauche; Christine K Olson; Andrea J Sharma

doi:10.1001/jamanetworkopen.2024.47492

COVID-19 Vaccine Reactogenicity Among Young Children

JAMA Netw Open. 2024 Nov 4;7(11):e2447492. doi: 10.1001/jamanetworkopen.2024.47492.

Authors

Sabrina A Madni¹, Kieauna Strickland^{1

2}, Victoria Konrad^{3

4}, Lauren Head Zauche¹, Christine K Olson^{1

5}, Andrea J Sharma^{1

5}

Affiliations

¹ Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
² Deloitte Consulting LLP, Atlanta, Georgia.
³ Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
⁴ GenTech Associates, Inc, Zionsville, Indiana.
⁵ US Public Health Service Commissioned Corps, Atlanta, Georgia.

PMID: 39585698
DOI: 10.1001/jamanetworkopen.2024.47492

No abstract available

Plain language summary

This cross-sectional study examines reactogenicity among children of participants in the Centers for Disease Control and Prevention COVID-19 Vaccine Pregnancy Registry from November 2022 to September 2023 to understand the frequency and types of reactions experienced.